Navigation Links
Replication in Medical Technology

Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data

... understanding of the protein chemistry of rapid replication enables us to develop synthetic vaccines specifically tailored to destroy or restrict replication of the targeted virus strains prior to an ... a new group of peptides related to the rapid replication function in viral and other diseases. The company ...

Replidyne Provides Strategic Update

... difficile-associated disease (CDAD), and its DNA replication inhibition program. As a result of ... REP3123 in the second half of 2008. About DNA replication Inhibition DNA replication is one of the essential steps in bacterial growth ...

Clinical Update - Debio 025 in Hepatitis C

... Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in the following clinical studies. Results of a phase Ib study ...

Clinical Update - Debio 025 in Hepatitis C

... Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in the following preclinical and clinical studies. Results of a ...

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus

... of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX-594, in addition to high-level active ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...

Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology

... of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX- 594, in addition to high-level ... novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously ...

Clinical Update - Debio 025 in Hepatitis C

... Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in preclinical studies. Previous results of a phase Ib study ...

Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA

... (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be ... works by inhibiting protease, an enzyme needed to complete the HIV replication process. The approved dose of APTIVUS is 500 mg taken with 200 mg of ...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... to stage two, in which the enrollment target is an additional 105 patients. Unlike other classes of HIV drugs that work to inhibit viral replication within human CD4+ cells, most of which are part of the immune system, vicriviroc is an HIV entry inhibitor designed to prevent the virus from ...

Gene Findings Unlocking Reasons for Neuroblastoma Risk

... Medicine. Scientists from six other centers in addition to Children's Hospital and the University of Pennsylvania contributed to the discovery or replication of the findings. Capasso et al, "Common variations in BARD1 influence susceptibility to high-risk neuroblastoma," Nature Genetics , ...

Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research

... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey replication (NCS-R). Archives of General Psychiatry, 2005 Jun;62(6):617-27. (8) Mauricio Tohen et al. (2007). Olanzapine versus Placebo in the Treatment of ...

IBM and EU Partners Create a Better Way to Fight AIDS Virus

... HIV genetic variant. EuResist is a powerful online system that helps doctors choose the treatment with the highest probability of halting virus replication and impairing evolution of drug resistance. Although there have been tremendous leaps and bounds in the management of the virus that causes ...

Autism Genes Discovered; Help Shape Connections Among Brain Cells

... Foundation. Scientists from 14 other centers in addition to Children's Hospital and the University of Pennsylvania contributed to the discovery or replication of the findings. Wang et al, "Common genetic variants on 5p14.1 associate with autism spectrum disorders," Nature , published online April 28, ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and ...

Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease

... differentiated adult neural stem cells for the cellular restoration and treatment of Parkinson's disease. Our original methodology is based on the replication of several steps in human neurogenesis to regenerate millions of mature neurons characterized before transplantation. These steps are essential to ...

Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer

... underway, three REOLYSIN(R) trials are now being sponsored by our collaborators." The primary objectives of the trial are to assess the presence, replication and anti-cancer effects of reovirus within liver metastases after intravenous administration of REOLYSIN(R) by examination of the resected tumour. ...

Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer

... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...

ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410

... studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... agent, is currently approved in oral form as 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules in Europe. Cytotoxic agents are designed to impact the replication of cells that divide rapidly, such as those in tumors. TEMODAL was initially approved in the European Union (EU) in 1999 for the treatment of ...

Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System

... many patients in the right situation." The MitraClip device creates a double orifice mitral valve by securing the leaflets to reduce MR in a replication of the surgical procedure pioneered by Ottavio Alfieri, MD. The resulting double orifice has an inherently smaller cross sectional area compared to ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is ...

Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus

... cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this ...

New Bisphenol A Study Has Limited Capability to Assess Human Health Effects

... useful for generating hypotheses that can be tested with more appropriate experiments or analyses. As noted by the authors of the study, independent replication and follow-up studies are needed to confirm their findings and to provide evidence on whether the associations are causal. Until such work has been ...

ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide

... provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist's to comparatively evaluate their most potent lead ...

Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO'08

... Lenexa, Kan., is eligible for a $420,000 convertible note to support the development of its therapeutic vaccine for HIV designed to inhibit viral replication by enhancing antibody and cellular immune response. The KBA investment will help the company secure an equal amount of funds from other sources. -- ...

Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients

... These data demonstrate potent antiviral activity and a favorable safety profile at all tested doses. "The profound inhibition of HIV-1 virus replication of IDX899 at doses of 400 and 200 mg daily confirm the potent antiviral activity previously reported at higher doses," said Dr. Robert Murphy, John ....

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

... About ANA598 ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation). PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is ...

Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting

... profile to Synagis(R) (palivizumab) in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its pivotal clinical trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated ...

Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases

... of the virus replikin concentration increases. Replikins are peptides, specified in virus genomes, which increase in concentration signaling rapid replication before virus outbreaks. This is the first report that cyclic increases in virus replikin concentration, each apparently building on the last, can be ...

Replidyne Discontinues Phase III Trial

... bacteria and C. difficile- associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research. Safe Harbor This press release contains plans, intentions, objectives, estimates and ...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

... the antiviral effect of subsequent treatment with interferon (8-fold decrease in concentration of interferon required to inhibit virus replication by 90%). "Data presented in each of these communications has provided important information in guiding the ongoing clinical development of ...

AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial

... to the volunteers at two dosage levels. A key design and safety feature of this single-cycle vaccine technology is that there is no further replication of the virus-like particles after the expression of the CMV proteins in the vaccine recipients. About CMV CMV is a herpesvirus that is a major ...

Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients

... product insert for information on this product. 4 Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results (39LB); 15th Conference on Retroviruses and Opportunistic Infections (CROI); ...

Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections

... the clinical observations of Genetic Immunity's founders. Their examination of the "Berlin Patient" proved that induction of immune control of HIV replication is feasible in an infected patient. The Company has developed the DermaVir Patch to induce the immune system to kill HIV infected cells specifically ...

deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes

... cancer programs, as well as the patients and researchers from 15 academic medical centers in Europe and the United States who took part in the replication of the discovery published today. How to order deCODE PrCa(TM) deCODE PrCa(TM) is performed in deCODE's Clinical Laboratory Improvement ...

New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy

... treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double- blind, ...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

... humans that average at least 10-fold higher than the serum-adjusted EC50. "This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral ...
Other Contents
(Date:9/22/2014)... Additive manufacturing (AM), or 3D printing, has rapidly ... metal components strong enough for structural applications. However, ... as well as quality standards to test the ... technology. Engineers at the University of Pittsburgh,s Swanson ... modeling and simulation (M&S) technology and new qualification ...
(Date:9/22/2014)... Sept. 22, 2014 NXT-ID, Inc. (NASDAQ: ... the growing mobile commerce market, issues the following corporate ... recent funding. Letter from the ... round of funding and joined the NASDAQ to support ... its other biometric and authentication products and services. This strategic ...
(Date:9/21/2014)... warming, are set to rise again in 2014 - reaching ... per cent projected rise in burning fossil fuels is revealed ... UK by researchers at the Tyndall Centre for Climate Change ... of Engineering, Mathematics and Physical Sciences at the University of ... Summit, where world leaders will seek to catalyse action on ...
Breaking Biology News(10 mins):Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3
(Date:9/23/2014)... September 23, 2014 Wellesley, Mass., September ... in its new report, Joint Reconstruction and ... market for joint reconstruction and replacement is expected to ... compound annual growth rate (CAGR) of 4.2% from 2013 ... the major regions, surging at a CAGR of 5.1%. ...
(Date:9/23/2014)... 2014 Given the nondiscretionary nature ... Fruit and Vegetable Markets industry is generally ... benefited operators over the five years to 2014. ... and demographic trends, including a focus on healthy ... capita fruit and vegetable consumption declined at an ...
(Date:9/23/2014)... "area under the curve of oxygen desaturation" (AUC Desat ... blood oxygen levels during procedures using sedation, according to ... , The AUC Desat provides information not only ... the depth, duration, and rate of episodes of oxygen ... of University of Cincinnati and colleagues reports on the ...
(Date:9/23/2014)... cancer in their lifetime and 20 per cent of ... researchers from the University of Leicester has helped Avacta ... system for diagnosing lymphoma in dogs in the early ... cLBT (canine lymphoma blood test), this is the first ... status of a dog after undergoing chemotherapy. , ...
(Date:9/23/2014)... NEW YORK, NY (PRWEB) September 23, 2014 ... the best innovators in the pharmaceutical industry with their ... honors, bestowed at a gala banquet at Gotham Hall ... marketers and brand managers representing top talent and brands. ... to celebrate its accomplishments,” says Anna Stashower, CEO and ...
Breaking Medicine News(10 mins):Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New hope for beloved family pets 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6
Other TagsOther Tags